𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Targeting the interleukin-6 receptor: A new treatment for systemic juvenile idiopathic arthritis?

✍ Scribed by Fabrizio de Benedetti; Alberto Martini

Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
79 KB
Volume
52
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Successful use of a humanized anti–inter
Successful use of a humanized anti–interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis
✍ Yasuaki Okuda; Kiyoshi Takasugi 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 329 KB 👁 1 views

## Abstract We report an excellent clinical response to treatment with a humanized anti–interleukin‐6 receptor antibody, tocilizumab, in a patient with progressive amyloid A (AA) amyloidosis complicating very active juvenile idiopathic arthritis. Treatment with tocilizumab immediately normalized th

The diagnostic significance of soluble C
The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor α-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis
✍ Jack Bleesing; Anne Prada; David M. Siegel; Joyce Villanueva; Judyann Olson; Nor 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 275 KB 👁 1 views

## Abstract ## Objective Macrophage activation syndrome is characterized by an overwhelming inflammatory reaction driven by excessive expansion of T cells and hemophagocytic macrophages. Levels of soluble interleukin‐2 receptor α (sIL‐2Rα) and soluble CD163 (sCD163) may reflect the degree of activ